Regulatory T cells as a potent target for controlling bone loss

Biochemical and Biophysical Research Communications

Volumn 402, Issue 2, 2010, Pages 173-176

  Yuan, Feng Lai ^a   Li, Xia ^a   Lu, Wei Guo ^a   Xu, Rui Sheng ^a   Zhao, Yi Qing ^a   Li, Cheng Wan ^a   Li, Jian Ping ^a   Chen, Fei Hu ^b  

^a NANTONG UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Bone loss; Osteoclasts; Osteoporosis; Regulatory T cells; Rheumatoid arthritis

Indexed keywords

CD28 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; BONE DENSITY; BONE DESTRUCTION; CELL COUNT; CELL DIFFERENTIATION; IN VITRO STUDY; IN VIVO STUDY; METABOLIC BONE DISEASE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SHORT SURVEY;

ANIMALS; ANTIGENS, CD28; ARTHRITIS, RHEUMATOID; BONE DENSITY; BONE RESORPTION; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MICE; MICE, TRANSGENIC; OSTEOCLASTS; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

MUS; MUS MUSCULUS;

EID: 78149469114     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.09.120     Document Type: Short Survey

References (54)

1. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
2. Nakashima T., Takayanagi H. Osteoclasts and the immune system. J. Bone Miner. Metab. 2009, 27:519-529.
3. Teitelbaum S.L. Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
4. Li X., Yuan F.L., Lu W.G., Zhao Y.Q., Li C.W., Li J.P., Xu R.S. The role of interleukin-17 in mediating joint destruction in rheumatoid arthritis. Biochem. Biophys. Res. Commun. 2010, 397:131-135.
5. Karlstrom E., Ek-Rylander B., Wendel M., Andersson G. RANKL induces components of the extrinsic coagulation pathway in osteoclasts. Biochem. Biophys. Res. Commun. 2010, 394:593-599.
6. Walsh N.C., Gravallese E.M. Bone remodeling in rheumatic disease: a question of balance. Immunol. Rev. 2010, 233:301-312.
7. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., Tanaka S., Kodama T., Akira S., Iwakura Y., Cua D.J., Takayanagi H. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J. Exp. Med. 2006, 203:2673-2682.
8. Rifas L. Bone and cytokines: beyond IL-1, IL-6 and TNF-alpha. Calcif. Tissue Int. 1999, 64:1-7.
9. Takayanagi H. New immune connections in osteoclast formation. Ann. NY Acad. Sci. 2010, 1192:117-123.
10. Van Bezooijen R.L., Van Der Wee-Pals L., Papapoulos S.E., Lowik C.W. Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. Ann. Rheum. Dis. 2002, 61:870-876.
11. Koshy P.J., Henderson N., Logan C., Life P.F., Cawston T.E., Rowan A.D. Interleukin 17 induces cartilage collagen breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann. Rheum. Dis. 2002, 61:704-713.
12. Kelchtermans H., Schurgers E., Geboes L., Mitera T., Van Damme J., Van Snick J., Uyttenhove C., Matthys P. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res. Ther. 2009, 11:R122.
13. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den Bersselaar L., Coenen-de Roo C.J., Joosten L.A., van den Berg W.B. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, Cartilage destruction, and bone erosion. Arthritis Rheum. 2004, 50:650-659.
14. Koenders M.I., Lubberts E., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., Di Padova F.E., Boots A.M., Gram H., Joosten L.A., van den Berg W.B. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am. J. Pathol. 2005, 167:141-149.
15. Kim Y.G., Lee C.K., Nah S.S., Mun S.H., Yoo B., Moon H.B. Human CD4+CD25+ regulatory T cells inhibit the differentiation of osteoclasts from peripheral blood mononuclear cells. Biochem. Biophys. Res. Commun. 2007, 357:1046-1052.
16. Zaiss M.M., Axmann R., Zwerina J., Polzer K., Guckel E., Skapenko A., Schulze-Koops H., Horwood N., Cope A., Schett G. Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum. 2007, 56:4104-4112.
17. Esensten J.H., Wofsy D., Bluestone J.A. Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat. Rev. Rheumatol. 2009, 5:560-565.
18. Saito S., Nakashima A., Shima T., Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am. J. Reprod. Immunol. 2010, 63:601-610.
19. Anderson A.E., Isaacs J.D. Tregs and rheumatoid arthritis. Acta Rheumatol. Port. 2008, 33:17-33.
20. Behrens F., Himsel A., Rehart S., Stanczyk J., Beutel B., Zimmermann S.Y., Koehl U., Moller B., Gay S., Kaltwasser J.P., Pfeilschifter J.M., Radeke H.H. Imbalance in distribution of functional autologous regulatory T cells in rheumatoid arthritis. Ann. Rheum. Dis. 2007, 66:1151-1156.
21. Lawson C.A., Brown A.K., Bejarano V., Douglas S.H., Burgoyne C.H., Greenstein A.S., Boylston A.W., Emery P., Ponchel F., Isaacs J.D. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25 high regulatory T cell population in peripheral blood. Rheumatology (Oxford) 2006, 45:1210-1217.
22. Shinoda K., Sugiyama E., Taki H., Harada S., Mino T., Maruyama M., Kobayashi M. Resting T cells negatively regulate osteoclast generation from peripheral blood monocytes. Bone 2003, 33:711-720.
23. Kelchtermans H., Geboes L., Mitera T., Huskens D., Leclercq G., Matthys P. Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis. Ann. Rheum. Dis. 2009, 68:744-750.
24. Zaiss M.M., Frey B., Hess A., Zwerina J., Luther J., Nimmerjahn F., Engelke K., Kollias G., Hunig T., Schett G., David J.P. Regulatory T cells protect from local and systemic bone destruction in arthritis. J. Immunol. 2010, 184:7238-7246.
25. Zaiss M.M., Sarter K., Hess A., Engelke K., Bohm C., Nimmerjahn F., Voll R., Schett G., David J.P. Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation. Arthritis Rheum. 2010, 62:2328-2338.
26. Salaun J., Corbel C., Le-Douarin N.M. Regulatory T cells in the establishment and maintenance of self-tolerance: role of the thymic epithelium. Int. J. Dev. Biol. 2005, 49:137-142.
27. Needham D.J., Lee J.X., Beilharz M.W. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem. Biophys. Res. Commun. 2006, 343:684-691.
28. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
29. Piccirillo C.A. Regulatory T cells in health and disease. Cytokine 2008, 43:395-401.
30. Allan S.E., Passerini L., Bacchetta R., Crellin N., Dai M., Orban P.C., Ziegler S.F., Roncarolo M.G., Levings M.K. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J. Clin. Invest. 2005, 115:3276-3284.
31. Mougiakakos D., Choudhury A., Lladser A., Kiessling R., Johansson C.C. Regulatory T cells in cancer. Adv. Cancer Res. 2010, 107:57-117.
32. Boissier M.C., Assier E., Biton J., Denys A., Falgarone G., Bessis N. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine 2009, 76:10-14.
33. Wilczynski J.R., Radwan M., Kalinka J. The characterization and role of regulatory T cells in immune reactions. Front. Biosci. 2008, 13:2266-2274.
34. Lopes J.E., Soper D.M., Ziegler S.F. Foxp3 is required throughout the life of a regulatory T cell. Sci. STKE 2007, 2007:pe36.
35. Wu Y., Borde M., Heissmeyer V., Feuerer M., Lapan A.D., Stroud J.C., Bates D.L., Guo L., Han A., Ziegler S.F., Mathis D., Benoist C., Chen L., Rao A. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006, 126:375-387.
36. Stroopinsky D., Avivi I., Rowe J.M., Avigan D., Katz T. Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacity. Eur. J. Immunol. 2009, 39:2703-2715.
37. Liu W., Putnam A.L., Xu-Yu Z., Szot G.L., Lee M.R., Zhu S., Gottlieb P.A., Kapranov P., Gingeras T.R., Fazekas de St Groth B., Clayberger C., Soper D.M., Ziegler S.F., Bluestone J.A. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 2006, 203:1701-1711.
38. Seddiki N., Santner-Nanan B., Martinson J., Zaunders J., Sasson S., Landay A., Solomon M., Selby W., Alexander S.I., Nanan R., Kelleher A., Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 2006, 203:1693-1700.
39. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 2003, 4:330-336.
40. Tai X., Cowan M., Feigenbaum L., Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat. Immunol. 2005, 6:152-162.
41. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., Kelly T.E., Saulsbury F.T., Chance P.F., Ochs H.D. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 2001, 27:20-21.
42. Le Bras S., Geha R.S. IPEX and the role of Foxp3 in the development and function of human Tregs. J. Clin. Invest. 2006, 116:1473-1475.
43. Cosmi L., Liotta F., Lazzeri E., Francalanci M., Angeli R., Mazzinghi B., Santarlasci V., Manetti R., Vanini V., Romagnani P., Maggi E., Romagnani S., Annunziato F. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood 2003, 102:4107-4114.
44. Apostolou I., von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 2004, 199:1401-1408.
45. Curotto de Lafaille M.A., Lafaille J.J. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?. Immunity 2009, 30:626-635.
46. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., Roncarolo M.G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997, 389:737-742.
47. Chen Y., Kuchroo V.K., Inobe J., Hafler D.A., Weiner H.L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994, 265:1237-1240.
48. Suzuki Y., Nishikaku F., Nakatuka M., Koga Y. Osteoclast-like cells in murine collagen induced arthritis. J. Rheumatol. 1998, 25:1154-1160.
49. Pettit A.R., Walsh N.C., Manning C., Goldring S.R., Gravallese E.M. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford) 2006, 45:1068-1076.
50. Westenfeld R., Ketteler M., Brandenburg V.M. Anti-RANKL therapy-implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density. Nephrol. Dial. Transplant. 2006, 21:2075-2077.
51. Pettit A.R., Ji H., von Stechow D., Muller R., Goldring S.R., Choi Y., Benoist C., Gravallese E.M. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am. J. Pathol. 2001, 159:1689-1699.
52. Jang T.J. The number of Foxp3-positive regulatory T cells is increased in Helicobacter pylori gastritis and gastric cancer. Pathol. Res. Pract. 2010, 206:34-38.
53. Yuan F.L., Li X., Lu W.G., Li C.W., Li J.P., Wang Y. The vacuolar ATPase in bone cells: a potential therapeutic target in osteoporosis. Mol. Biol. Rep. 2010, 37:3561-3566.
54. Price S. TREG cells block bone loss in vivo. Nat. Rev. Rheumatol. 2010, 6:436.